» Articles » PMID: 36828947

Early Detection of Adverse Drug Reaction Signals by Association Rule Mining Using Large-Scale Administrative Claims Data

Overview
Journal Drug Saf
Specialties Pharmacology
Toxicology
Date 2023 Feb 24
PMID 36828947
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Adverse drug reactions (ADRs) are a leading cause of mortality worldwide and should be detected promptly to reduce health risks to patients. A data-mining approach using large-scale medical records might be a useful method for the early detection of ADRs. Many studies have analyzed medical records to detect ADRs; however, most of them have focused on a narrow range of ADRs, limiting their usefulness.

Objective: This study aimed to identify methods for the early detection of a wide range of ADR signals.

Methods: First, to evaluate the performance in signal detection of ADRs by data-mining, we attempted to create a gold standard based on clinical evidence. Second, association rule mining (ARM) was applied to patient symptoms and medications registered in claims data, followed by evaluating ADR signal detection performance.

Results: We created a new gold standard consisting of 92 positive and 88 negative controls. In the assessment of ARM using claims data, the areas under the receiver-operating characteristic curve and the precision-recall curve were 0.80 and 0.83, respectively. If the detection criteria were defined as lift > 1, conviction > 1, and p-value < 0.05, ARM could identify 156 signals, of which 90 were true positive controls (sensitivity: 0.98, specificity: 0.25). Evaluation of the capability of ARM with short periods of data revealed that ARM could detect a greater number of positive controls than the conventional analysis method.

Conclusions: ARM of claims data may be effective in the early detection of a wide range of ADR signals.

Citing Articles

Pharmacy-led interventions to reverse and prevent prescribing cascades in primary care: a proof-of-concept study.

Mohammad A, Hugtenburg J, Ceylan Y, Kooij M, Knies S, Van den Bemt P Int J Clin Pharm. 2025; .

PMID: 39954224 DOI: 10.1007/s11096-025-01873-8.


Safety of combined drug use in patients with cardiovascular and cerebrovascular diseases: an analysis based on the spontaneous reporting database of adverse drug reactions in Hubei Province.

Wang J, Zhao Y, Chen Z, Huang R Front Pharmacol. 2025; 15():1451713.

PMID: 39845792 PMC: 11751046. DOI: 10.3389/fphar.2024.1451713.


A Comparative Study Assessing the Incidence and Degree of Hyperkalemia in Patients on Unfractionated Heparin versus Low-Molecular Weight Heparin.

Naseralallah L, Nasrallah D, Koraysh S, Aboelbaha S, Hussain T Clin Pharmacol. 2024; 16:33-40.

PMID: 39677557 PMC: 11646396. DOI: 10.2147/CPAA.S487288.


Predicting Drugs Suspected of Causing Adverse Drug Reactions Using Graph Features and Attention Mechanisms.

Yang J, Hu Z, Zhang L, Peng B Pharmaceuticals (Basel). 2024; 17(7).

PMID: 39065673 PMC: 11279999. DOI: 10.3390/ph17070822.

References
1.
Takeuchi Y, Shinozaki T, Matsuyama Y . A comparison of estimators from self-controlled case series, case-crossover design, and sequence symmetry analysis for pharmacoepidemiological studies. BMC Med Res Methodol. 2018; 18(1):4. PMC: 5759844. DOI: 10.1186/s12874-017-0457-7. View

2.
Naranjo C, Busto U, Sellers E, Sandor P, Ruiz I, Roberts E . A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981; 30(2):239-45. DOI: 10.1038/clpt.1981.154. View

3.
Downing N, Shah N, Aminawung J, Pease A, Zeitoun J, Krumholz H . Postmarket Safety Events Among Novel Therapeutics Approved by the US Food and Drug Administration Between 2001 and 2010. JAMA. 2017; 317(18):1854-1863. PMC: 5815036. DOI: 10.1001/jama.2017.5150. View

4.
Schotland P, Racz R, Jackson D, Soldatos T, Levin R, Strauss D . Target Adverse Event Profiles for Predictive Safety in the Postmarket Setting. Clin Pharmacol Ther. 2020; 109(5):1232-1243. PMC: 8246740. DOI: 10.1002/cpt.2074. View

5.
Yildirim P . Association Patterns in Open Data to Explore Ciprofloxacin Adverse Events. Appl Clin Inform. 2016; 6(4):728-47. PMC: 4704041. DOI: 10.4338/ACI-2015-06-RA-0076. View